Antimicrobial Tools and Resources

Access to antimicrobial tools can aid researchers in the discovery of new anti-infective treatments for cystic fibrosis.

3 min read
In this article

Why Antimicrobial Tools Are Important

Pulmonary infections, due to infectious agents such as bacteria, viruses, and fungi, are a common occurrence in people with cystic fibrosis. While effective treatments are available for some of these common pathogens, various drug-resistant strains of bacteria have developed that make treatment difficult.

Certain research tools, such as clinical isolates of Pseudomonas aeruginosaBurkholderia cepacia complex, and other bacterial strains are available for CF research purposes and can aid scientists in the discovery of new anti-infective therapies.

Model Systems for CF Antimicrobial Research

For information on in vivo murine models to study anti-microbial agents in CF, contact:

Tracey Bonfield, Ph.D. D (ABMLI) 
Assistant Professor, Department of Pediatrics
Case Western Reserve University

tracey.bonfield@case.edu
Tel: 216-368-6896

 

References

Microbial Resources

Clinical isolates of P. aeruginosa (bacterial strains isolated from the lungs of people with CF) are recommended for research areas including new drug discovery, biofilm research, virulence studies, and drug-resistance studies.

CF isolates of Staphylococcus aureus (including MRSA), Stenotrophomonas maltophilia, and Achromobacter xylosoxidans also are available.

For more information, contact:

Rafael E. Hernandez, M.D., Ph.D.
Infectious Disease
Seattle Children's Research Institute
CFisolatecore@seattlechildrens.org
CF Isolates Core

***

B. cepacia complex and other non-fermenting bacterial isolates can be requested from the CF Foundation-supported B. cepacia Research Laboratory and Repository at the University of Michigan, Ann Arbor.

For more information, contact:

John J. LiPuma, M.D.
Professor, Pediatrics and Epidemiology
University of Michigan

jlipuma@umich.edu
Tel: 734-615-5909
Fax: 734-764-4279

References

***

Nontuberculous mycobacteria (NTM) isolates can be requested through the CF Foundation-supported Research Development Program Culture, Biorepository, and Coordinating Core at National Jewish Health, Denver. The core provides isolates to researchers on request and after committee review. Requests can be made by species or other characteristics, and many isolates have associated meta-data including whole genome sequencing, phylogenomic analysis, and antimicrobial susceptibility information available.

Currently, this collection has over 1,000 NTM isolates, including longitudinal isolates collected through the CF Foundation-supported diagnostic (PREDICT: NCT02073409) and treatment (PATIENCE: NCT02419989) trials.

For more information, contact:

Rachael Rodger, MPH
Clinical Research Coordinator
National Jewish Health Advanced Diagnostic Laboratory
Colorado Cystic Fibrosis Research & Development Program

RodgerR@njhealth.org
Tel: 303-270-2753
Fax: 303-398-1953

Microbial Informatics

Advances in gene sequencing technology have enabled sequencing of two common CF bacterial genomes: Pseudomonas aeruginosa and Burkholderia cepacia.

Understanding the importance of this resource for the research community, the Cystic Fibrosis Foundation supports the construction of annotated databases that serve as a central portal through which researchers may access high-quality genome-associated information about the bacteria and its potential drug/vaccine targets.

View the Pseudomonas Genome Database and the Burkholderia Genome Database.

Share this article
Topics
Researcher Resources
Was this information helpful?
Have questions? We’re here to help. Call us at 1-800-FIGHT CF

(1-800-344-4823)
Mon - Thu, 9 am - 7 pm ET
Fri, 9 am - 3 pm ET

 

More Ways To Get Help